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ETHICAL DECISION MAKING IN COMMITTEE. 
THE ROLE OF REVIEW BOARDS AND ETHICS 
COMMITTEES 
IN HEALTH CARE, HEALTH POLICY AND 
MEDICAL RESEARCH 
Committees and responsabilities 
From the crib to the grave: committees, committees, committees. 
Committees have become a part of our life; some of us are members of com- 
mittees; al1 of us depend on decisions made or recommended by committe- 
es, we don't know and by members we don't know, - anonymous bodies, 
making decisions for others by majority vote. Our generation has seen the 
mushrooming of committees al1 over the world and for al1 possible issues, 
including committees for patient care in the hospital, for setting health care 
policy on the local, provincial or national level, for supervising the ethical 
practice of research on humans, for health education, and committees within 
professional groups and organizations in the nursing, medical, and resear- 
ching professions. 
What is the morale or the reason behind the culture of decision making 
by committee? 1s there a higher authority of moral judgment if made by a 
group of people rather than by one individual? And, if committees make 
moral judgments and ethical decisions, will these committees also be 
morally or legally liable for decisions the same way a competent individual 
has to be hold liable morally and legally for her or his actions? And what is 
the personal moral or legal liability of individual members of committees; to 
whom to they owe responsibility: to nobody except to their individual cons- 
cience, or to those who elected them to be a member of that committee, or 
to the constituency they are expected to represent whether elected by that 
group or not? Personal experiences and empirical research suggest that the 
answer to these questions might rather be NO than YES. Each of these ques- 
tions is full of philosophical, cultural and political complexities which we 
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cannot address in detail today; but it is important to keep these questions in 
mind in order to be aware that decisioiri by committee is only one of many 
other model of deciding, accepting responsibility, setting rules, policy or 
strategy, drafting regulations or recommendations, distributing public or pri- 
vate funds, or making recommendations for policy options to other bodies. 
Two arguments have been voiced to support the mushrooming of com- 
missions and committees: (a) the need for expert advice in complex political, 
social, and interdisciplinary issues, and (b) the need for participatory repre- 
sentation of the stakeholders involved. Keeping the fragile nature of decision 
making and recornrnendation making in committee in mind, 1 will discuss three 
different types of committees in the area of health care: (a) commissions on 
the state or national or transnational level, (b) research review boards, requi- 
red for human experimentation and innovative therapy, and (c) hospital ethics 
committees setting rules for hospitals or wards and focussing on individual 
patient's care. 
Policy stting Committes on the proviricial or state level 
For commissions on the state level it is very important, that they focus (a) 
on identifying different views of the world and (b) on options for societal con- 
sent or on means to live with dissent, if consent cannot be achieved. Sometimes 
a commission has to deal with issues such as abortion for which the arguments 
pro and contra have been voiced for centuries, sometimes the analytical frarne- 
work has not been constructed such as in the case of genetic screening or xeno- 
transplantation. In both cases the commission has to provide analytical 
justification from first principles either for consensus formation or for policy 
options on how to live with dissent. The US National Commission's Belmont 
Report, for example, broke new intellectual grounds by identifying for a post- 
modern, pluralistic society the principles of autonomy, nonmaleficence, bene- 
ficence and justice as the leading first principles for establishirig either con- 
sensus or reasoning in favor of acceptance of individually different positions 
in the respect of the dignity of the individual religious or moral conscience. 
More fundamental, philosophical bioethical analysis - such as writing books 
on general theories of justice - is best done by those whose job is to think and 
write, not a group of commissioners selected because of their national promi- 
nence, professional background, political connections, and ideological affilia- 
tions. 
An international, national or state committee can articulate others' posi- 
tions, filter information, and facilitate communication among policy makers. 
Legally nonbinding declarations of high moral binding such a.s UNESCO's 
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declaration Sor the protection of the human genome are easier to be achieved 
and to becorne valid than regulations or international conventions such as the 
EU Bioethics Convention which still needs to jump the parliamentary hurdles 
of some countries and need transformation into national law. Given the fact 
that declarations and regulations in bioethics al1 are targeted at protecting the 
individual fellow human as a person and as persons happen to and have every 
right to disagree, there are certain lirnits as to what can be declared and regu- 
lated. Among the number of goals and means of policy oriented ethics eom- 
mittees, let us bnefly discuss the following nine [see also R Cook-Deegan, in: 
Sass 19881: 
( 1 )  Searching for a compromise: Some public issues arise so qiiickly that 
controversy surfaces as a symptom of incomplete analysis by different factions. 
In such cases, there is an opportunity to articulate a position that could be 
widely accepted. In political terms, this is extremely useful because democra- 
tic govemmí:nt is erected on consensus, although constrained by unalienable 
individual rights, as the philosophers of the Age of Reason have stressed. 
Human gene therapy is an example: consensus that somatic cell gene therapy 
is little diffeirent form other medical technologies was voiced first by the US 
President's C:ommission and then by the US Congress Office of Technology. 
This was sufficient to prevent legislation to prohibit or limit it. The US 
President's Cornmission report on defining death, and many of the CS National 
Commission's reports on human research subjects also exemplify this function 
of forming the point of condensation for consensus. Consensus formation is 
ideally suited to national commissions or ad hoc commissions. The funda- 
mental~ of religions and worldviews might be quite different and exclusive to 
each other, bilt as Jesus has demonstrated in the parable of the Good Samaritan, 
there are certain mid-leve1 ethical principles, such as solidarity, reciprocity, 
'neighbor's love', that can be shared by many different ideational commit- 
ments. 
(2) Clarijication of values and understanding of disagreements: 
Consensus does not always forrn around issues, even when a technology is the 
main new feature. Nuclear power and arms control have not been notable for 
their rational public discourse or clean and highly analytical policy process. In 
bioethics connmissions, the objective may be consensus but the result may be 
incompatible views, as we have seen in the debates on abortion and most 
recently on stem-cell research. The process of articulating dissent is nonethe- 
less valuable Seeking consensus may also contribute to public debate with no 
expectation tlhat concrete recommendations are possible. Thus consensus-see- 
king need not be considered a failure if it yields progress but no end. There is 
ample value in ventilating disparate moral positions publicly. An illusory or 
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forced consensus can result in policy change only to breed later backlash as 
the policy encounters resistance. The classical ethical principle to govern a pro- 
cedural proposal rather than a content solution is the principle of subsidiarity, 
the rule, that at the lowest possible societal leve1 and by those most directly 
involved decision should be made, and that larger societal or political bodies 
should only take action when individuals and groups most directly involved 
demonstrate that they are unable to solve conflicts or provide help and support 
to those in need. In socialethics, this principle has proven to be of great value; 
elsewhere 1 have recommended that its use should be tested in bioethics also. 
(3) Identifying emerging issues: National cornrnissions can identify futu- 
re issues. This can be quite helpful to policy makers even if no conclusions are 
reached about options for dealing with the issues. "Early warning" functions 
constitute specific, narrow, example of consensus formation. The focus is on 
identifying issues likely to matter in the future rather than on solutions to 
current policy concerns. If a set of issues is agreed to be important in the futu- 
re, then a politician can begin to formulate his or her positions on those issues, 
and to comrnit resources to finding out about them. In Germany, we basically 
had not much public debate or a national ethics committee studying the impact 
of nuclear energy on attitudes and individual and group risk assessment; unfor- 
tunately only later we had those debates, when billions of Deutsche Mark had 
already been employed and when nuclear energy facilities were already in use. 
(4) Mitigating a societal debate andprobable consensus: If an issue very 
new to the public and to experts and politicians, public policy as well as public 
discourse may very well benefit from a debate that pits the best minds of 
various camps against one another in a mutually respecting forum. More often, 
however, little value will be added by the commission's deliberations. Fetal 
research is an example of an issue that has been addressed by the US National 
Commission, then an Ethics Advisory Board, and was to be addressed by 
BEAC (US Bioethics Advisory Council). No action to break up the ideological 
logjam has been effective. 
Even if consensus is not possible, a softening of positions al the extreme 
edges may be. If this occurs, the environment for making tough policy choi- 
ces may be less threatening, and incremental policy adjustments may become 
possible. Some issues bound to elude consensus are relatively easy to identify. 
They usually have been hotly debated for years (e.g., human rights, fetal rese- 
arch, abortion, access to health care, surrogate motherhood, homosexuality, 
cloning, organs for sale). Changes on such issues require either extended care- 
ful thought, followed by changes in public attitudes, or classical political 
maneuvering to which ethical analysis contributes little. If continuing a con- 
troversial debate is the objective, there is generally little to be gained by having 
a national commission. 
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Success,ful as a means and as a moderator for pi~blic discourse were two 
national conimissions in Denmark, one addressing the issue of brain-death, the 
other acceptance and validation of Advance Medical Directives. Both initiati- 
ves went oví:r a few years and funds were disbursed for supporting a debate in 
the academia, in neighborhoods, in churches and organizations; only after such 
an extended debate initiated, but not moderated or controlled by the commis- 
sion, the Danish parliament was ready to pass legislation on both issues. 
(5) Canzouflaging governmental desinterest or inaction resulting in post- 
ponement ofissues: It is quite common for politicians to be evasive or cowar- 
dice in regad to malung hard choices in the public's best interest, such as in 
health care finance reform or in social security and old-age pension issues. The 
choices to be made are mostly unpopular and to not win immediate support; 
but immedisite support and success is important for politicians depending on 
the electorate's vote. To insta11 a blue-ribbon committee or an expert group for 
further studies is a widely used tool to postpone or to neglect decisions. 
Members of' those committees are in quite difficult professional and ethical 
position: on one side they are allowed and asked to contribute their visions, 
ideas and expertise, and on the other side they very clearly recognize that most 
likely nothirig will come out of their work, that they are actually contributing 
to increasing problems by putting them on the back-burner. 
Politiciiins often hope that controversies will go away. They may seek to 
use a 'study' or a 'committee' as a delaying tactic, judging that the intensity of 
conflict will dissipate over the course of a mandated study. A ciosely related 
tactic is for politicians to cal1 for a study, while politically maneuvering to dis- 
tance themselves from its results. When the results are produced, they can 
accept the rí:sults they agree with, and blame the commission for those they 
reject. 
(6) Proposing Regulations or Drafting Legislation: A committee can, 
having identified an existing consensiis, devise a way to incorporate it into 
practice. In the US, the President's Commission served this role in a multitude 
of issues. Ita report on 'Defining Death' served this function, as the temglate 
for statutes passed in the States. The US National Commission reports on chil- 
dren, prisoni:rs, and other vulnerable populations were readily translated into 
federal regulations governing research. In Congress, this function is uaually 
gerformed by committees, which have access to outside expertise and focus it 
on legislation. Executive agencies also have policy-making groups that per- 
form analogous functions. From time to time, however, policy makers may 
wish to atterid explicitly to the ethical dimensions of a policy choice. In such 
cases, a national cornmittee or ad hoc panel is the logical choice. In Germany, 
we have so-called Enquete-Commissions for genetic technologies, instituted 
by and repoiting to the national parliament. I 
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(7) Creating and Providing a Critlcal Mass of Ethical Exlierts: Ethics 
Committees serve as educational means in interdisciplinary, academia-public, 
and theory-practice interaction and experience of members of different pro- 
fessional and social background. It is not easy to find philosophers who des- 
pite their expertise in one or the other field of philosophy are capable of fin- 
ding the common language and method of working in a team of physicians, 
regulators, lawyers and scientists. The same is true of the other professions. 
Interdisciplinary committees are the best breeding ground for crossdisciplinary 
understanding and evaluating. 
A societal effort to incorporate ethical analysis into public policy rests on 
an academic reservoir of technical experts, legal scholars, and hurnanists. If no 
critica1 mass of people in these fields exists, then the first step in any program 
must be to develop one. Grants and training programs are the direct means to 
this end. If there is sufficient expertise iii the various fields, then ad hoc com- 
mittees, state committees, or permanent review boards are al1 possibilities. 
Choosing among these options will depend on the number of issues at hand, 
the resources available, and the objectives of seeking advice. 
If consensus is a likely outcome, and publicity is desirable, then an inde- 
pendent blue ribbon committee is the logical choice. Care must be taken, 
however, to provide sufficient budget and time. Funds and schedules must, in 
particular, allow for the extensive network formation necessary for a proper 
job. If there are many issues and the decision making apparatus is complex, 
then a permanent analytical agency is the option of choice. In this case, the 
extra investment in a management structure is necessary in addition to the 
report-writing team or teams. 
(8) Debating and Confronting Special Interest Group Lobbying: The 
modern world of public policy and public discourse is not only influenced by 
cornmittees of various kind, even more so by lobby groups and special interest 
gioups, actually dominating those issues of their specific interest. Interest 
groups have become much more sophisticated in their use of national direct 
mail fund-raising, organization of national letter-writing campaigns, boycotts, 
and other tactics. They have introduced a new dynarnic into the political pro- 
cess. They are organized around specific issues, and establish a staff, newslet- 
ters, policy analysis mechanisms, and capacities for political strategy that once 
formed can be applied to new issues as they arise. The great strength of interest 
groups is their narrow focus, which pennits them to concentrate on a specific 
agenda. But this can also be a weakness, as it tends to result in fixed policy 
positions that once taken are-extremely difficult to modify. A narrow focus can 
lead to parochial policy formulations; consequences of policy recommenda- 
tions may not take account of their broader Pmpact outside the sphere of inte- 
rest and thus are not in the interest of thie public and most likely will not last. 
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The abortioi? debate definitely is overdominated by special interest groups in 
al1 countries in Europe and the Americas; new areas for special interest groups 
are environrnent, genetic modification of cultured animals and plants, animal 
research, eui.hanasia, in vitro fertilization, cloning, and fetal and stem cell rese- 
arch. 
(9) Special Roles for Provincial or other Ethics Comrnittees on the Grass- 
root Level: As far as 1 see, not enough consideration has been given to the role 
of ethics cornmittees initiating public moral discourse and debate and develo- 
ping public policy options on the provincial level. In a politically coordinated 
Europe, the role of nation states will dirninish, and so will the role and autho- 
rity of national ethics cornrnittees. The role of European harmonization will be 
increased and as a counterpart to this, new roles and responsibilities should be 
developed for the provincial level. In Germany, we have quite a difference of 
priorities in public culture and moral concern in more religiously oriented sta- 
tes such as Bavaria and more secular cultures such as in the northern part of 
Germany. Other nation states have similar differences based on tradition and 
attitude in different provinces and areas of the country. As we have seen, e.g. 
the availability of organ-sharing has increased, since information, education 
and promotion of organ donation has been concentrated on the provincial level. 
This is a list of issues, where societal ethics comrnittees on a provincial 
level close to the individuals and institutions they serve can have an impact on 
consensus fcmnation and the improvement of ethical quality in political, pro- 
fesional anti institutional decision making: (1) access to long-term c a e ;  (b) 
financing ht:alth care; (3) providing moral and medical quality control on 
various levels: (4) setting priorities; ( 5 )  setting guidelines for governing use of 
human research subjects in hospital, nursing homes, home cae ,  and ambula- 
tory settings , (6) setting guidelines in organ-sharing for transplantation in acti- 
vely promoting organ-sharing on the grass-root level; (7) setting guidelines for 
confidentiality of results from tests for AIDS, drug dependency, and genetic 
properties; fiinally (8) assessing the prime values, virtues and priciples which 
might this province or community apart from neighboring others. 
Research review committees 
Clinical research is a noble enterprise in itself, socially not only 
acceptable but ethically required on moral, cultural, religious, and huma- 
nitarian grounds. There is no philosophical or religious tradition in the 
world, that does not support and require mutual aid among fellow-humans, 
solidarity with the weak and needy, and research for the improvement of 
support, help and care for those who are sick, suffering, or in pain. In 
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modern times, strong European humanist and Christian traditions have ste- 
warded and encouraged clinical research for the benefit of the patient and 
pioneered in the establishment of morally acceptable forms of kuman expe- 
rimentation, developing rational and responsible procedures in clinical 
trials for the protection of research subjects. 
Ethically unacceptable forms and goals in research design, such as con- 
centration camp experiments by the Nazis and the Japanese or the Tuskegee 
syphilis studies in the United States, were the exemption rather than rule and 
have given rise to heightened ethical awareness and the development and 
improvement of procedures for good clinical practice in Europe and in most 
civilized countries. Ethics Committees for clinical research and new therapy 
have been in force in Prussia since the end of the last century, recluiring a res- 
ponsible balance of harm, risk, and benefit and introducing the principle of 
informed consent, without which no human experimentation should be allo- 
wed and accepted. Since the first introduction of the Helsinki-Tokyo 
Guidelines for Human Experimentation review boards have become a legal 
requirement for clinical trials al1 over Europe and in most civilized countries. 
Principies of 'nonmaleficence'and 'benefit over ham', 'respect far autonomy' 
and 'informed consent' have become essential features in Good Clinical 
Practice (GCP). 
The mandate of the clinical ethics committees always is to primarily 
see into the risk-benefit balance, the informed-consent issue. Clinical ethics 
committees doe not accept responsibility for the actual research which 
stays with the research teams. Clinical ethical committees in general have 
are required to include at least one ethicist, one legal expert, one lay person 
representing the neighborhood, one pharmacologist, and a minimal num- 
ber of physicians of different subpecialization. But size and membership 
vary widely. Only a very few clinical ethics committees in Germany have 
ac'tually philosophers or theologians as members, while their absence in 
those committees would be unthinkable of in the US. The clinical center at 
the US National Institute of Health has a rather large number of nine or 
more members, given the highly specialized research areas; al1 ethics com- 
mittee protocols are to be reviewed by the head of the clinical ethics divi- 
sion and signed by the director of the clinical center. Georgetown 
University Hospital follows another model, having a rather small ethics 
committee, but decisions are prepared for the ethics committee by expert 
committees beforehand; the director of the hospital will have to sign the 
decisions of the ethics committee, andl there are cases where he has refu- 
sed to do so and given the protocol back to the committee and the appli- 
cant, mostly because of issues related to informed consent and the langua- 
ge in informed consent forms. As the parameters and duties of clinical 
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ethics cominittees are already well established, let me focus on three cru- 
cial issues which will overshadow the debate in the future: (1) can ethics 
be taught and can an expertise in clinical ethics deliberation be developed; 
(2) are there special requirements for cross-cultural and miiltinational miil- 
ticenter studies; (3) has the informed consent principle come to the end of 
its usefulness and should it be replaced by a more appropriate model siich 
as the 'informed request' model or a 'contract model'? 
(1) Can ethics be taught? Here is my thesis: Ethical principles and bioet- 
hical assessinent can be taught the same way logic, rational modes of analysis, 
asaessment, and cognitive knowledge can be taught. But ethical behavior is an 
attitude which is as much independent from conceptual analysis as irrational 
behavior of those who have very well been trained in logic, rational strategy, 
and assessrient of nsk. It is well known that knowing the rules and laws does 
not prevent individuals from violating rules and breaking laws: the better rules 
are understciod, the more sophisticatedly can they be broken, circumvented or 
bend. Nevertheless, teaching bioethics in the medical and the clinical research 
setting intends to improve ethical knowledge, assessment skills, and the embo- 
diment of moral attitudes into the day-to-day work of research and clinical care. 
If we would live in ideologically closed societies, there would be no need 
for professional ethical teaching as the role of the professions would be deter- 
mined by tkie forces of ideological and political power and ethics would be 
replaced by exercises in dominance and subordinance. Teaching ethics in a 
multicultural environment therefore is the superior way to assess and to con- 
firm values, virtues, principles, human and civil rights, and to support consen- 
sus formation and coordinated action on various levels of private and profes- 
sisnal activity. Bioethics, along with other ethics in highly advanced areas of 
decision macing, production, and research, additionally has to face the fact that 
there are certain ethical challenges, for which traditional moral authonties such 
as Moses or Jesus, Aristotle or Kant never gave direct guidance, such as for 
how to deal clinically with human experimentation or genetic predictions, 
endstage chironic diseases, artificial modes of making babies, or how to treat 
fellow-humans with irreversible and full brain damage in the presence of 
highly advai~ced medical capabilities. 
While cognitive knowledge can be taught and learned, attitudinal affir- 
mation or cl.iange is more complex and cannot be guaranteed even by the best 
teaching methods. This is confirmed by a US survey among young physicians 
who had attended bioethical classes as part of the required clinical curriculum 
demonstrated that only 3% of them actually changed their system of belief and 
concept of ethics as a result of those teachings while 94% declared that their 
attitudes in general have been formed prior to attending professional schools. 
Their understanding of clinical ethics was strongly influenced by clinical expe- 
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rience (68%), role model behavior of their clinical teachers (63%), by peer dis- 1 
cussion (53%) and by family tradition (58%). As far as specific awareness of 
issues in clinical ethics were concemed, lphysicians thought that classes in bio- ~ 
ethics improved communication skills with patients (83%), sensitivity ini pallia- 
tive care (52%), partnership with patients in clinical decision making (68%), 
protecting patient's privacy (56%); but i,n issues of public controversy bioet- 
hics teaching did not change understanding and attitudes: abortion (12%), defi- 
nition of death (16%), withholding of treatment from severely handicapped 
newboms (7%) or organ donation (5%). While we have no such empincal data 
yet from Europe, experiences with mandatory courses in bioethics within 
medical curricula suggest that results inight not be much different. As the 
majority of medical curricula in the European Community does not have requi- 
red courses in bioethics yet, it is important to introduce medical humanities 
into the core curriculum, and also into continuing medical education. Bioethics 
education for clinical research has to be an essential part of bioethics teaching 
in general, but additionally there should be specific and highly targeted bioet- 
hics training for researchers and research tearns, also for members of research 
ethics committees. 
Teaching bioethics in medical education does not intend to compete with 
teaching philosophy in philosophy departments, but adds skills of moral and 
cultural analysis and assessment to quality education in medical practice and 
medical research. Bioethics teaching has two goals: (1) It helps physicians and 
researchers in quality control and quality assurance of care and sf  research by 
integrating 'blood status' and 'value status' of the patient in individualized dif- 
ferential diagnosis and to treat the patient according to her or his individual 
understanding of quality of life, risk profile, expectations, feai-S and hopes. 
Clinical data, ethical principles, and personal data of the individual patient 
together will form the basis for individualized prognosis, goals of therapy and 
therapeutic intervention. (2) The protection of human and civil right.7 of pro- 
bands and patients has to be based on a commonly shared strong bioethical and 
legal platform, which does not compromise with local customs os cultural atti- 
tudes who do not live up to these standards. The European and WHO regula- 
tions for GCP define such quality standards, which must not be dlowed to be 
violated even if not protected by national laws or safeguarded by cultural atti- 
tudes. 
Because of the practica1 relevance of bioethics teaching, the methods of 
teaching must primarily be based on case studies, scenario assessment, eva- 
luation of principles, virtues and vices, points-to-consider lists and regulations. 
It is more important that physicians leani to apply bioethical pnnciples in real- 
life situations of clinical conflict than mastering the arcane walks in ivory- 
tower theories of arnbiguous authority. 
I 
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Here is a seven point list of concepts which have to be entertained in bio- 
ethics teaching specific to researchers, regulators, and members of ethics com- 
mittees: (1) It is not acceptable that investigators or ethics committees force 
their particular view on values or weltanschauung on others, the least on those 
vulnerable ft:llow humans whose life or wellbeing depends on their actions. (2) 
Basic philo~~ophical or religious have to be left to the individual while basic 
human and civil right issues, including those regulating clinical research, have 
to be left to i:he respective regulatory or legislative authorities. (3) No research 
can ever be done without appropriate approval by the research subject, and the 
form and coritent of consent, request, or approval has to be checked carefully, in 
particular regarding those whose capacity to approve is or might be impaired. 
(4) Clinical research is a process the biomedical, biometrical, and bioethical 
parameters of which might change during the course of the trial; therefore a 
one-time purictual review prior to the begin of the trial does not guarantee hig- 
hest levels of subject protection and quality of the trial. (5) To review the out- 
come of trials not only on biomedical and biometrical grounds but on bioethical 
grounds as ~vell, is very educational and will improve future trial design and 
trial procedures. (6) While the four-phase randomized controlled clinical trial 
(RCT) has become the research model of choice and is supported by a multitu- 
de of rules and expectations among researchers, ethicists, regulators, and poli- 
ticians, othei? avenues of research such investigational new drug trials (INB), 
participatory models of risk-and-benefit-sharing with patients and probands, and 
biometrical s r  biomedical alternatives to human experimentation, including 
csmputer sirnulation, use of historical data, cell-, tissue-, and animal-research, 
has to become a routine part of the evaluation and education process. (7) Of par- 
ticular educational and strategic importance is the evaluation of morally con- 
troversial feiztures such as randomization, double-blind-studies, placebo con- 
trol versus available alternative drug control, tennination of the trial, breaking 
the code etc.; these challenges occur again in clinical research and therefore 
should belong to the core topics in bioethics education. 
(2) Ethical challenges in multicenter clinical trials: As most clinical trials 
are conducteid in multi-center studies, often including centers in different coun- 
tries regulated by different legal and regulatory parameters and cultural and 
professional attitudes, the harmonization and quality assurance of bioethical 
standards is of prime importance and rightly has become the focus of the 
European Commission. It is self-evident, that good ethical practice in multi- 
center cliniciil trials can only be assured by coordinated and integrated bioet- 
hics education across the centers and nations involved and by harmonization 
in the ethical design and quality control of the trial. 
Of particular importance is the fair and equal treatment of subjects in mul- 
ticenter trials across the borders of states and cultures. In biometrical issues we 
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already enjoy a high degree of coherent and fully integrated statistical quality. 
We should strive for similar degrees of bioethical quality control and clinical 
research design. The following six features should be considered to implement, 
to improve, and to harmonize the biomefsical as well as bioethical quality and 
equality of trials: (1) A bioethics coordinator or coordinating team, compara- 
ble to the coordinator recommended by GCP rules would be charged with 
coordinating bioethical review and assessment prior, during and after the trial; 
the coordinator also would be available for acute or routine consultation on 
bioethical issues at each of the centers for investigators and local review com- 
mittees. (2) Prior to initiating the trial the development of a specific bioethical 
'points to consider ' list and specific case studies would sensitize those invol- 
ved, speed up the process, and help in creating and improving a common bio- 
ethical language and modes of analysis, assessment, and judgment. A bioethics 
training and harmonization workshop including the heads of local research 
teams and review boards, the sponsor, insurers and regulators discussing his- 
toric cases of comparable moral and medical risk and prospective cases which 
might occur in the intended trial would improve the strength and design of any 
large-scale trial. Such a workshop would be imperative if complex cross-natio- 
nal legal and cross-cultural ethical issues are involved. (3) A concerted action 
of centers involved, and including sponsors and whenever possible regulators 
and insurers, should prior to the beginning of the trials decide on crucial bio- 
ethical issues such as (a) placebo control, (b) bioethical and biometrical selec- 
tion of subjects, (c) language and content of informed consent foms, (d) modi- 
fication of routine procedures in RCT's and GCP, and (e) define moral and 
clinical uncertainties regarding risk or haim. (4) While the regulatjons for GCP 
require a bioethics review for discontinued trials, it would be extremely edu- 
cative and would contribute to quality assurance of trials if at the end of al1 
trialsfinal bioethics review and result report, together with the biomedical and 
biometrical results and reports, would routinely be put together. ( 5 )  It would 
also improve design quality and bioethics standards if informed consent forms 
would be developed and tested prior to the beginning of the trial. (6) The input 
from research subjects during and after the trial will be one of the best tools in 
continuing research ethics training and in improving the bioethical! setup of the 
trial during its course. Also it would be very important to learn from patient's 
input for future trials of similar bioethical risk; the bioethics literature on cli- 
nical research ethics focusses increasingliy on issues of patient's input ad res- 
ponse. 
The Bochum Center for Medical Ethics has developed a generic points- 
to-consider list of ten questions, which then will have to lead into the deve- 
lopment of more specific lists regarding specific ethical and medical risk of the 
trial. Here are the ten specific questions: (1) 1s the trial design optimal from a 
160 Hans Martin Sass 
medical-ethical perspective? (2) 1s this particular trial necessary? (3) Did the ' 
patient give his or her informed consent? (4) Was the information completely 
or incomplete given or understood? (5) Could there be reasons that consent 
was not fully voluntary? (6) What principles of justicelfairness were used in 
selecting patients? (7) Does the patient know about hisher right to terminate 
participatiori at any time? 1s such termination technically possible? (8) Will 
there be an ongoing cornmunication with the patient during the trial? Who s 
personally responsible for continued communication with the patient? ((9) 
Define confliicts between the interest of research, the presumed interest of the 
patient and interest of the patient as expressed by himselfherself. (9) How do 
you handle these conflicts of interest? Discuss these conflicts with your patient. 
An evein more specific list for phase 1 cytostatica trials has the following 
four questicins: (1) 1s your definition of efficiency as expressed in terms of 
remission o.r no change in conflict with the patient's definition of quality of 
life? (2) Which health index profiles or checklists did you use in communica- 
ting with thiv patient? Do you have your own standardized point-to-consider 
list, especially designed for this particular trial? (3) 1s the patient aware of a 
possible scanty prognosis for full recovery? What does the patient expect form 
the trial? What does the researcher expect? (4) Has the patient been offered 
best available palliative care? Has helshe been made aware that best palliative 
care will coiitinue even if helshe withdraws from the participating in the trial? 
(3) Infclrmed request or a contract model replacing the inforrrzed consent 
principle?: 'The discussion of specific ethical issues in multicenter trials raises 
the question whether or not the traditional informed consent model still is good 
enough to s~ct he highest possible ethical quality standard. Elsewhere 1 have 
proposed to replace the consent model with a contract model. Let me briefly 
sketch the concept of the contract model. 
It has become a routine in GCP and in clinical trial regulation to require 
infomzed celnsent of research subjects prior their inclusion in the trial and to 
inform about their right to withdraw from the trial anytime. The 'informed con- 
sent' principle is an essential feature in al1 clinical trials and required by 
govemmental regulations from the beginning of this century. But just asking 
for consent is a soft paternalistic principle and not the appropriate expression 
of the subject's autonomy. Other risky scenarios in the professional and per- 
sonal setting are handled by principles more appropriate to shared risk and 
partnership in communication and cooperation: models of 'participatory con- 
tract' or informed request. Times and challenges in clinical trials have chan- 
ged since A B Hill's successfully demonstrated the four-phase model of ran- 
domized controlled trials in his 1948 streptomycin research. Today, after 
decades of successful clinical trials and progress in bioethical reasoning and 
experience many research issues such as randomization, placebo control, high 
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risk evaluation, uncertainty assessment and acceptance, data pirotection, and 
patient's or proband's benefit cannot be comfortable and ethically handled wit- 
hin such a model of soft paternalism. 
Areas of clinical where the traditional model of soft paternalism becomes 
particularly troublesome include at least the following three: (1) very high 
medical or moral risk such as adventures in phase 1 oncological trials in infer- 
tility research; (2) issues of data protection and probable benefit or h m  which 
go well beyond the realms of traditional trials involving only the research sub- 
ject proper and nobody else, such as in predictive genotyping for early health 
risk recognition and for drug delivery based on individual properties in drug 
metabolism; (3) issues surrounding the storage of human cells, tissue or other 
properties for which new avenues of data protection, research subject's bene- 
fit, as well as pedigree harm-and-benefit features have to be identified, asses- 
sed, and managed in an ethically responsible fashion. Most of these areas will 
need new forms of risk sharing and new models of communication-in-trust and 
cooperation-in-trust between sponsors, regulators, insurers, investigators, 
patients and their families and friends. 
Participatory models such as a more formal contractual relationship bet- 
ween subjects and researchers or principies of a more active 'informed request' 
by the patient rather than the more passive principle of 'informed consent' 
should be introduced and tested by sponsors, investigators, insurers, and 
patients, and evaluated by ethics committees and multicenter trid workshops. 
Therefore, as research ethics committees will have to guarantee, haimonize, 
and improve the good ethical practice of well established procedures in GCP, 
bioethics education and training also has to look into new avenues of meeting 
the bioethical challenges in more recent areas of clinical investigations which 
warrant new features of participatory responsibility and risk-and-benefit sha- 
ring among, sponsors, researchers, regulators, patients and their families. 
Hospital ethics committees 
Hospital ethics comrnittees are the least known and least widely used ins- 
truments to improve the medical and moral quality of patient care on the grass- 
root level, in the ward, on the bedside. The US journal HEC (for: Hospital 
Ethics Committees) provides the best insight into the discussions and deve- 
lopments in this field. 
In thehospital, we clearly have to differentiate between two types of com- 
mittees, (1) the decision making and policy setting committee, defining the 
moral character of a hospital or a wardl and (2) the consulting committee in 
individual patient care. 
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(1) The decision making committee does not address individual cases, rat- 
her sets policy and determines the ethical profile of a hospital or a ward. A cat- 
holic Hospital, e.g. most likely will set the ethical rule, that abortion are not 
performed at al1 or only in the most rare situations of immediate threat of death 
to the pregnant woman; at the same time a municipal hospital funded by tax- 
payer's m0ne.y and being responsible to and serving a wider constituency pro- 
bably should have at its moral priority to respect the pregnant woman's repro- 
ductive choices. It must be normal, that in pluralistic societies rich in diffeient 
worldviews, beliefs and attitudes different providers of health care offer diffe- 
rent sets of vialues and virtues. The corporate identity and the corporate profi- 
le and corporate ethics will be different from institution to institution, thereby 
serving as a corporate profile to the potential client and patient and as a gui- 
dance in educating and training staff, nurses and physicians. 
(2) Totally different from the decision making model is the bedside ethics 
committee eeraluating ethical conflicts and ethical requirements in actual indi- 
vidual cases. There seems to be a common understanding that bedside ethics 
committees should not take away responsibility from attending physicians and 
their team as this would be counterproductive for good patient care and against 
the tradition lof physician's ethics to accept final responsibility for the indivi- 
dual patient. IBut bedside ethics comrnittees may serve as a sounding board and 
discourse medium to analyze issues and conflicts and to evaluate options for 
individual patient care, thus helping the physician to form and to defend her or 
his own course of action. Many model of hospital ethics committees have been 
experimented with and it would lead too far to discuss them all. Also, some 
hospitals have one or two individual clinical ethics specialists, often a retired 
senior physician or a priest, performing similar duties as a bedside ethics com- 
mittee would do. 
Instead of a conclusion 
In a 197 5 review of US Presidential Advisory Commissions from Truman 
to Nixon Wolanin writes: 'Commissions are uniquely capable of analyzing pro- 
blems because they are temporary systems; they can recruit well-qualified 
members andl staff; they have unusually good access to expertise and data; and 
they serve as an integrative framework for an interdisciplinary and multi-inte- 
rest consideration of problems. Commissions are also particularly capable of 
persuading oithers to accept as authoritative the findings and recommendations 
because they can command a wide audience for their findings ....; they have a 
decision-making process that conforms to the public's ideal of how decisions 
shsuld be made; and they enjoy the benefits of being both inside and outside 
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the govemment.'[p.41] These are quiet positive remarks on public advisory 
committees; but there are less favorable experiences as well wifh ethics com- 
mittees. 
From a European perspective, 1 should balance this positive account with 
recalling Jean Jaques Rousseau's proposal to differentiate between the volon- 
tee generale [expressing and formulating human rights and human obligations] 
and a volontee de tous [a majority vote which by its sheer majority or umani- 
mity may cal1 for the most inhuman actions out of mass-hysteria or funda- 
mental ideologies shared by al1 as the dark days of the inquisition or the holo- 
caust demonstrate quite clearly], reminding us that even unanimous votes by 
this or that ethics committee does not guarantee good ethical quality nor pro- 
tection of citizens or patients from exploitation or discrimination. 
Common sense teaches that a too easy consensus within a group or com- 
mittee might not be in the interest of those depending on these anonymous 
committees. Therefore, a prime ethical and analytical rule for ethics cornmit- 
tees in the presence of societal or religious dissent should be to strive for the 
protection of the individual patient's or citizen's own personal decision in 
health care matters based on very personal beliefs, goals and values As a gol- 
den rule for al1 sorts of ethics committees one could formulate: as long as and 
whenever philosophers, theologians, physicians, scientist, lawyers, and politi- 
cians of different background disagree, then they have an obligation to form a 
consensus on the protection of the individual conscience, values and wishes as 
the true and essential expression of human dignity. 
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